Breyanzi

{
  "id": "MLC-T-ONC-001251",
  "term": "Breyanzi",
  "field": "Oncology and biomedicine",
  "definition": "A treatment used for adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma, or certain types of large B-cell lymphoma that relapsed (came back) or did not get better after treatment with at least one or two lines of systemic therapy. It is also being studied in the treatment of other types of cancer. Breyanzi is made using a patient’s T cells (a type of immune system cell). A gene for a special receptor called chimeric antigen receptor (CAR) is added to the T cells in the laboratory. These changed T cells called CAR T cells are grown in large numbers in the laboratory and given to the patient by infusion. Breyanzi binds to a protein called CD19, which is found on most B-cell lymphoma cells. This helps the body’s immune system kill cancer cells. Breyanzi is a type of cellular immunotherapy called CAR T-cell therapy. Also called lisocabtagene maraleucel.",
  "synonyms": [
    "lisocabtagene maraleucel"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/breyanzi/"
}